RU2008123406A - Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента - Google Patents

Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента Download PDF

Info

Publication number
RU2008123406A
RU2008123406A RU2008123406/15A RU2008123406A RU2008123406A RU 2008123406 A RU2008123406 A RU 2008123406A RU 2008123406/15 A RU2008123406/15 A RU 2008123406/15A RU 2008123406 A RU2008123406 A RU 2008123406A RU 2008123406 A RU2008123406 A RU 2008123406A
Authority
RU
Russia
Prior art keywords
patient
cancer
level
sample
ill
Prior art date
Application number
RU2008123406/15A
Other languages
English (en)
Russian (ru)
Inventor
Скотт УИЛХЕЛМ (US)
Скотт Уилхелм
Джеймс ЭЛТИНГ (US)
Джеймс ЭЛТИНГ
Original Assignee
Байер Хелскеа эЛэЛСи (US)
БАЙЕР ХЕЛСКЕА ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байер Хелскеа эЛэЛСи (US), БАЙЕР ХЕЛСКЕА ЭлЭлСи filed Critical Байер Хелскеа эЛэЛСи (US)
Publication of RU2008123406A publication Critical patent/RU2008123406A/ru

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2008123406/15A 2005-11-14 2006-11-14 Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента RU2008123406A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73585405P 2005-11-14 2005-11-14
US60/735,854 2005-11-14

Publications (1)

Publication Number Publication Date
RU2008123406A true RU2008123406A (ru) 2009-12-27

Family

ID=37814675

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008123406/15A RU2008123406A (ru) 2005-11-14 2006-11-14 Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента

Country Status (12)

Country Link
US (1) US20070178494A1 (https=)
EP (1) EP1963849A2 (https=)
JP (1) JP2009515553A (https=)
KR (1) KR20080073745A (https=)
CN (1) CN101454668A (https=)
AU (1) AU2006315592A1 (https=)
BR (1) BRPI0618597A2 (https=)
CA (1) CA2629860A1 (https=)
MX (1) MX2008006239A (https=)
RU (1) RU2008123406A (https=)
WO (1) WO2007059094A2 (https=)
ZA (1) ZA200804509B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
EA010485B1 (ru) 2003-07-23 2008-10-30 Байер Фамэсьютиклс Копэрейшн Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты)
SG160364A1 (en) * 2005-03-07 2010-04-29 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
BRPI0617488A2 (pt) * 2005-10-21 2011-07-26 Bayer Healthcare Llc mÉtodo para a monitoraÇço do estado de uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente, mÉtodo de seleÇço de terapia para um paciente humano com uma doenÇa e mÉtodo de dignàstico para detectar uma doenÇa associada a uma via de vegf-165 ativada por ultra-expressço ou por mutaÇço de proteÍna vegf-165 em um paciente
CA2628091A1 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20100008910A1 (en) * 2006-09-12 2010-01-14 John Chant Methods and compositions for the diagnosis and treatment of cancer
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100311106A1 (en) * 2008-01-25 2010-12-09 Hartmann Lynn C Quantitation of lobular involution for breast cancer risk prediction
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
EP2156834A1 (en) * 2008-08-08 2010-02-24 S.I.F.I - Società Industria Farmaceutica Italiana - S.P.A. Ophthalmic pharmaceutical compositions comprising Sorafenib for the treatment of neoangiogenic pathologies of the eye
JP5439494B2 (ja) * 2008-10-21 2014-03-12 バイエル ヘルスケア エルエルシー 肝細胞癌と関連するシグネチャ遺伝子の同定
BR112012007762A2 (pt) * 2009-10-07 2021-11-16 Koninklijke Philips Electronics Nv Método de avaliação do nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer, produto de programa de computador, sistema (200) para avaliar o nível de toxicidade de um paciente que se submete a um protocolo de tratamento de câncer
CN102053150B (zh) * 2009-10-30 2013-07-17 上海交通大学医学院附属瑞金医院 一种人成骨肉瘤干细胞相关抗原标记物及其应用
AU2011281706A1 (en) * 2010-07-19 2013-01-10 F. Hoffmann-La Roche Ag Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
EP2601528B1 (en) * 2010-08-02 2015-10-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Novel methods for predicting the responsiveness of a patient affected with a tumor to a treatment with a tyrosine kinase inhibitor
WO2012081898A2 (ko) 2010-12-13 2012-06-21 사회복지법인 삼성생명공익재단 위암의 예후 예측용 마커 및 이를 이용하는 위암의 예후 예측 방법
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION
WO2013173384A1 (en) * 2012-05-16 2013-11-21 Dale Wong Method and system for sorting biological samples
EP2971101A2 (en) * 2013-03-15 2016-01-20 Janssen Pharmaceutica N.V. Assay for predictive biomarkers
US10017823B2 (en) * 2013-04-25 2018-07-10 Cbs Bioscience, Co., Ltd Analytical method for increasing susceptibility of molecular targeted therapy in hepatocellular carcinoma
RU2546035C1 (ru) * 2014-04-15 2015-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ прогнозирования развития метастазов у больных меланомой кожи
RU2643761C1 (ru) * 2017-08-10 2018-02-05 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ расчета прогноза раннего прогрессирования меланомы кожи
WO2019074920A1 (en) * 2017-10-10 2019-04-18 Oncocyte Corporation METHODS AND COMPOSITIONS FOR THE DETECTION AND DIAGNOSIS OF BREAST CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635421B1 (en) * 1997-12-09 2003-10-21 Children's Medical Center Corporation Neuropilins and use thereof in methods for diagnosis and prognosis of cancer
US20030232400A1 (en) * 2002-12-20 2003-12-18 Susan Radka Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
WO2005009367A2 (en) * 2003-07-17 2005-02-03 Ambit Biosciences Corporation Treatment of diseases with kinase inhibitors
BRPI0508970A (pt) * 2004-03-19 2007-08-21 Penn State Res Found método combinatórios e composições para o tratamento de melanoma

Also Published As

Publication number Publication date
EP1963849A2 (en) 2008-09-03
CN101454668A (zh) 2009-06-10
JP2009515553A (ja) 2009-04-16
CA2629860A1 (en) 2007-05-24
MX2008006239A (es) 2008-12-12
WO2007059094A2 (en) 2007-05-24
ZA200804509B (en) 2009-05-27
AU2006315592A1 (en) 2007-05-24
BRPI0618597A2 (pt) 2011-09-06
US20070178494A1 (en) 2007-08-02
KR20080073745A (ko) 2008-08-11
WO2007059094A3 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
RU2008123406A (ru) Способ мониторирования эффекта от лечения у больного раком пациента (варианты) и способ оценки состояния больного раком пациента
Yano et al. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer
Kebebew et al. A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer
Goitein et al. Mapping of ghrelin gene expression and cell distribution in the stomach of morbidly obese patients—a possible guide for efficient sleeve gastrectomy construction
RU2017126701A (ru) Способ детекции нуклеосом, содержащих нуклеотиды
De Vogelaere et al. Gastrointestinal stromal tumor of the stomach: progresses in diagnosis and treatment
Liu et al. Overexpression of lysine-specific demethylase 1 is associated with tumor progression and unfavorable prognosis in Chinese patients with endometrioid endometrial adenocarcinoma
Marberger et al. Novel approaches to improve prostate cancer diagnosis and management in early‐stage disease
KR101903838B1 (ko) 유방암 관련 stk32c 유전자 및 이의 용도
CN115166245A (zh) Clu及其组合物在诊断胆管癌中的应用及胆管癌诊断试剂盒
Dolly et al. Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy
Fugane et al. Prognostic impact of preoperative cachexia in patients undergoing major hepatopancreatobiliary surgery for malignancy
ES2436667B1 (es) Suero biomarcador para diagnosticar el cáncer colorrectal
CN104321649A (zh) 用于诊断阿扎胞苷耐药性的试验
Johns et al. Diagnosis and staging of equine neoplasia
RU2012100904A (ru) Биомаркер желудочно-кишечного рака
CN102724981A (zh) 针对肝细胞癌症患者的化学疗法的治疗效果预测方法
RU2275636C1 (ru) Способ прогнозирования рецидивов в мочевой пузырь у больных раком почечной лоханки и мочеточника после радикального хирургического лечения
US10316319B2 (en) Composition for diagnosis of liver metastasis of colorectal cancer and the use thereof
RU2585122C1 (ru) Способ прогнозирования метастазов в печени при раке прямой кишки
JP2022531319A (ja) 癌の検出法
JP7742129B2 (ja) 大動脈瘤の診断、治療剤、および、治療剤のスクリーニングのための新技術
Tropé et al. Unsettled questions regarding ovarian cancer.
RU2012100905A (ru) Биомаркер er2 для гинекологического рака
Mysliwiec et al. T1110 A Colorectal Cancer Screening Outreach Using Fecal Immunochemical Tests

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20110722